Discontinued ProductPF 06447475 (Cat. No. 5716) has been withdrawn from sale for commercial reasons.
Potent LRRK2 inhibitor (IC50 = 3 nM). Attenuates α-synuclein-induced dopaminergic neurodegeneration and neuroinflammation in G2019S-LRRK2 expressing rats. Also neuroprotective in wild type rats. Brain penetrant.
Sold for research purposes under agreement from Pfizer Inc
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Daher et al (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J.Biol.Chem. 290 19433 PMID: 26078453
Henderson et al (2015) Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J.Med.Chem. 58 419 PMID: 25353650
View Related Products by Product Action
Keywords: PF 06447475, PF 06447475 supplier, PF06447475, potent, LRRK2, inhibitors, inhibits, neurodegeneration, neuroinflammation, brain, penetrant, 5716, Tocris Bioscience
Citations for PF 06447475
Citations are publications that use Tocris products.
Currently there are no citations for PF 06447475.
Reviews for PF 06447475
There are currently no reviews for this product. Be the first to review PF 06447475 and earn rewards!
Have you used PF 06447475?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.